ClearOne entered into an Agreement and Plan of Merger to acquire Cortigent, with Vivani receiving 12,500,000 ClearOne shares as consideration. The Consideration Shares are subject to lock-ups, with half locked for one year and the remainder for two years. Closing is subject to shareholder approvals, Nasdaq listing, effectiveness of a Form S-1, and completion of a concurrent $10–$15 million financing in unit form. The post-close board will have five members, and ClearOne will observe a 12-month equity issuance moratorium subject to exceptions.
Agreement details:
- Agreement type: Agreement and Plan of Merger
- Counterparty: Cortigent and Vivani
- Signed / Effective: Jul 01 2026 / same
- Duration / Termination: Up to 180 days to close
- Reason: Acquire Cortigent and combine operations for growth
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.